RSV MONOCLONAL ANTIBODY (INFANTS)
On August 3rd, the ACIP voted unanimously and recommended the use of Sanofi and AstraZeneca’s Beyfortus™, a monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) for newborns and infants below 8 months of age born during or entering their first RSV season. The ACIP also voted to recommend Beyfortus™ for children aged 8 to 19 months who are at increased risk of severe RSV disease and entering their second RSV season.
To review a summary of the meeting click here.
The official recommendation was recently published in the MMWR and will be incorporated into the 2023 CDC Immunization Schedule accordingly. Shipping is expected to begin mid-September. The VFC program is also expected to incorporate Beyfortus™ into their portfolio in early October but please note that individual state implementation timelines may vary.
Next Steps
If your practice is considering administering Sanofi’s Beyfortus™ this fall to infants be prepared to code and bill using this guide.
As practices review the clinical information for Beyfortus™, we recommend reaching out to your major payers to make sure adequate payment is in place. If the members of your clinical team have any questions about Beyfortus™ please contact your local Sanofi representative or call Sanofi’s customer service at 1-800-822-2463.
RSV (ADULTS 60+)
During their June meeting, the ACIP recommended a dose of RSV vaccine for older adults 60 years of age and older using shared decision-making between the patient and healthcare provider. Unlike routine and risk-based vaccine recommendations, recommendations based on shared clinical decision-making do not target all persons in a particular age group or an identifiable risk group.
These details were published in the MMWR at the end of July, which is typically a signal to insurance carriers to begin paying for the newly approved vaccines. We recommend reaching out to your major payers to make sure adequate payment is in place before incorporating any new vaccine into your routine schedule.
The CDC is hosting a webinar on August 30th to discuss General Information and Clinical Guidance. Click here for more information and to register.
CPP MEMBER PRICING
We will be sending updated pricing sheets and member discount information in the coming weeks to include new vaccines that will be available this fall. For any additional questions, contact the CPP office.
